Last reviewed · How we verify
NCT02403375: Insight Kids
Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes
NA trial testing Accu-Chek Insight Pump System in Diabetes Mellitus Type 1 in 43 participants. Completed in 26 October 2017.
26 October 2017
Quick facts
| Lead sponsor | Hoffmann-La Roche |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 43 |
| Start date | 17 May 2015 |
| Primary completion | 26 October 2017 |
| Estimated completion | 26 October 2017 |
| Sites | 9 locations across Austria, United Kingdom, Germany |
Drugs / interventions tested
- Accu-Chek Insight Pump System
Conditions studied
- Diabetes Mellitus Type 1 — all drugs for Diabetes Mellitus Type 1 →
Sponsor
Hoffmann-La Roche — full company profile →
Who can join
Adults 2 to 17, any sex, with Diabetes Mellitus Type 1. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to compare metabolic control, treatment satisfaction, and quality of life during continuous subcutaneous insulin infusion (CSII ) therapy with a new insulin pump system with multiple daily injections (MDI) therapy. Furthermore, this study will add clinical data originating from clinical investigation in a special population, i.e. children and adolescents of ages 2 - 17 years , to the existing clinical data of the ACCU-CHEK Insight insulin pump.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02403375
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus Type 1
Currently open trials in the same condition.
- NCT07091318 — CBTi for the Treatment of Insomnia in Type 1 Diabetes · EARLY_PHASE1 · recruiting
- NCT07320495 — Efficacy and Safety of the APGO Algorithm for Automated Insulin Delivery · NA · recruiting
- NCT06936280 — Type 1 Diabetes and Diabetes Distress · NA · recruiting
Other Hoffmann-La Roche trials
Trials by the same sponsor.
- NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
- NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
- NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
- NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
- NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02403375 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
- Last refreshed: 27 November 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02403375.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing